Evogene Ltd.
EVGN
$0.59
-$0.01-1.39%
NASDAQ
| 12/31/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -79.65% | 146.62% | -44.08% | 166.96% | 708.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -79.65% | 146.62% | -44.08% | 166.96% | 708.37% |
| Cost of Revenue | 230.06% | -59.52% | 389.35% | 73.87% | 325.83% |
| Gross Profit | -331.49% | 133.51% | -78.71% | 372.78% | 841.04% |
| SG&A Expenses | -26.81% | 8.32% | -40.55% | -27.79% | -2.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.41% | 14.94% | -28.31% | -38.96% | 5.12% |
| Operating Income | -43.28% | 42.46% | 9.78% | 54.56% | 41.06% |
| Income Before Tax | -639.19% | 10.10% | 50.51% | 113.49% | 46.03% |
| Income Tax Expenses | -100.00% | -- | -- | 275.00% | -200.00% |
| Earnings from Continuing Operations | -643.03% | 10.10% | 50.51% | 113.40% | 46.14% |
| Earnings from Discontinued Operations | 98.38% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -89.58% | -61.31% | 2,333.33% | -41.30% | -120.36% |
| Net Income | -1,343.33% | 17.66% | 33.03% | 106.47% | 39.12% |
| EBIT | -43.28% | 42.46% | 9.78% | 54.56% | 41.06% |
| EBITDA | -23.05% | 47.30% | -0.41% | 45.13% | 45.41% |
| EPS Basic | -316.57% | 42.00% | 49.93% | 121.55% | 48.71% |
| Normalized Basic EPS | -- | -- | -- | -- | 44.48% |
| EPS Diluted | -316.57% | 42.00% | 49.93% | 121.55% | 48.71% |
| Normalized Diluted EPS | -- | -- | -- | -- | 44.48% |
| Average Basic Shares Outstanding | 53.03% | 42.05% | 33.74% | 12.63% | 18.70% |
| Average Diluted Shares Outstanding | 53.03% | 42.05% | 33.74% | 12.63% | 18.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |